APP and Alzheimer disease: Cathepsin B has been previously reported to be upregulated in brain tissues from APP/PS1 transgenic mice, and changes in Cathepsin B showed a similar direction in healthy mice and the serum of AD patients relative to control patients, making Cathepsin B a potential biomarker of AD (Sun et al., 2015).